Tolerability and safety of biological therapies for psoriasis in daily clinical practice: A study of 103 Italian patients

Acta Dermato-Venereologica

Volumn 91, Issue 1, 2011, Pages 44-49

  Brunasso, Alexandra Maria Giovanna ^a,b   Puntoni, Matteo ^c   Salvini, Camilla ^d   Delfino, Chiara ^e   Curcic, Pero ^f   Gulia, Andrea ^g   Massone, Cesare ^f  

^a Departments of Environmental Dermatology and Venereology   (Austria)

^b Departments of Dermatology   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d Prato Hospital   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Adalimumab; Adverse events; Efalizumab; Etanercept; Infliximab; Psoriasis; Safety; Tolerability

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE THROMBOCYTOPENIA; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; BRONCHITIS; CLINICAL FEATURE; CLINICAL PRACTICE; COHORT ANALYSIS; COLON CARCINOMA; CONGESTIVE HEART FAILURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENITAL HERPES; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE REACTION; LIVER CARCINOMA; LUNG CARCINOMA; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MILIARY TUBERCULOSIS; NEUROLOGIC DISEASE; PANCYTOPENIA; PAPULAR RASH; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; YOUNG ADULT;

EID: 78751496653     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0959     Document Type: Article

References (24)

1. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-1565.
2. Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, et al. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat 2007; 18: 76-83.
3. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
4. Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009; 160: 162-169.
5. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274-285.
6. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008; 158: 1107-1116.
7. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7-15.
8. Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag 2007; 3: 245-258.
9. Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, et al. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol 2008; 7: 1137-1146.
10. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35: 869-876.
11. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol 2005; 141: 82-84.
12. Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-262.
13. Breslow NE, Day NE. Statistical methods in cancer research: vol II - the design and analysis of cohort studies. International Agency for Research on Cancer. New York: Oxford University Press 1987: p. 59-100.
14. EMEA Press office. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). Available from: http://www.emea.europa.eu/humandocs/PDF/EPAR/raptiva/2085709e.
15. Brunasso AM, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. J Am Acad Dermatol 2009; 60: 781-785.
16. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129: 886-890.
17. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-1017.
18. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-1869.
19. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of antitumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008; 20: 431-435.
20. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344.
21. Pincelli C, Henninger E, Casset-Semanaz F. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab. Arch Dermatol Res 2006; 298: 329-338.
22. Thielen AM, Kuenzli S, Saurat JH. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005; 211: 209-217.
23. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-231.
24. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.